To develop a new tool to assess constraints due to urinary treatments in neurological patients.
A prospective, monocentric study has been conducted from January to May 2017. Out-patients (multiple sclerosis, spinal cord injury, Parkinson disease) were included in a referral center if they had LUTS treatment for at least 3 months. To validate psychometric properties, we conducted a literature review, qualitative interviews, and discussion with a panel of six experts. Comprehension, acceptation, and pertinence were tested by a pilot study. A validation study, designed to calculate content validity, internal consistency reliability, and test-retest reliability [intraclass correlation coefficient (ICC)] has been conducted. The primary outcome was good psychometric properties defined with Cronbach's α > 0.7 and ICC > 0.7.
Comprehension, acceptation, and pertinence were excellent. Validation study showed a perfect content validity (r2 = 1) and excellent internal consistency reliability (Cronbach' α = 0.90). Total score was between 0 (best score) to 66 (maximal constraints). Test-retest reliability calculated using ICC was 0.81. Time to fill questionnaire was 4 min 20 s. The final version was composed by 22 items.
LUTS TCA is the first validated tool to assess constraints of urinary treatment and has excellent psychometric properties.
World journal of urology. 2018 Dec 04 [Epub ahead of print]
Nicolas Turmel, Pierre Lévy, Claire Hentzen, Camille Chesnel, Audrey Charlanes, Samer Sheikh-Ismael, Gérard Amarenco, Philippe Manceau
GREEN GRC 01 UPMC Sorbonne Universite, Hôpital Tenon, Service de Neuro-Urologie, 4 Rue de la Chine, 75020, Paris, France. ., Departement de Sante Publique Et Unité de Neurophysiologie Clinique Hopital Tenon (APHP), UPMC and Inserm UMR S 1136 (EPAR Team) 4, Rue de la Chine, 75970, Paris Cedex 20, France., GREEN GRC 01 UPMC Sorbonne Universite, Hôpital Tenon, Service de Neuro-Urologie, 4 Rue de la Chine, 75020, Paris, France.